Bronte Capital Management Pty Ltd. Regeneron Pharmaceuticals, Inc. Transaction History
Bronte Capital Management Pty Ltd.
- $944 Million
- Q1 2025
A detailed history of Bronte Capital Management Pty Ltd. transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Bronte Capital Management Pty Ltd. holds 154,693 shares of REGN stock, worth $75.8 Million. This represents 10.4% of its overall portfolio holdings.
Number of Shares
154,693
Previous 152,783
1.25%
Holding current value
$75.8 Million
Previous $109 Million
9.85%
% of portfolio
10.4%
Previous 11.06%
Shares
18 transactions
Others Institutions Holding REGN
# of Institutions
1,470Shares Held
85.8MCall Options Held
1.39MPut Options Held
1.45M-
Vanguard Group Inc Valley Forge, PA9.41MShares$4.61 Billion0.11% of portfolio
-
Black Rock Inc. New York, NY8.45MShares$4.14 Billion0.2% of portfolio
-
Jpmorgan Chase & CO New York, NY5.66MShares$2.77 Billion0.28% of portfolio
-
State Street Corp Boston, MA4.79MShares$2.35 Billion0.13% of portfolio
-
Capital International Investors Los Angeles, CA3.99MShares$1.96 Billion0.52% of portfolio
About REGENERON PHARMACEUTICALS, INC.
- Ticker REGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 107,190,000
- Market Cap $52.6B
- Description
- Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...